Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Gains from Investment Securities (2016 - 2026)

Insmed's Gains from Investment Securities history spans 17 years, with the latest figure at $2.4 million for Q1 2026.

  • Quarterly Gains from Investment Securities rose 123.18% to $2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $184.5 million through Mar 2026, up 37.81% year-over-year, with the annual reading at $20.7 million for FY2025, 3.15% up from the prior year.
  • Gains from Investment Securities came in at $2.4 million for Q1 2026, down from $18.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $104.7 million in Q3 2025 to a low of -$21.6 million in Q4 2022.
  • The 5-year median for Gains from Investment Securities is $5.2 million (2022), against an average of $18.0 million.
  • Year-over-year, Gains from Investment Securities soared 1222.46% in 2024 and then tumbled 1737.36% in 2025.
  • Insmed's Gains from Investment Securities stood at -$21.6 million in 2022, then surged by 108.97% to $1.9 million in 2023, then skyrocketed by 1222.46% to $25.7 million in 2024, then fell by 27.97% to $18.5 million in 2025, then crashed by 87.25% to $2.4 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Gains from Investment Securities are $2.4 million (Q1 2026), $18.5 million (Q4 2025), and $104.7 million (Q3 2025).